1 min read
Add as a preferred source on GoogleEditas Wins Australia Clearance as Wells Fargo Upgrades Rating
Australian authorities cleared a Phase 1/2 gene-editing trial, while Wells Fargo moved its Editas rating from Equal Weight to Overweight.
Editas Medicine received Australian clearance for a Phase 1/2 trial of its gene-editing therapy Thursday, while Wells Fargo upgraded the biotech to Overweight from Equal Weight.
The regulatory decision allows the trial to proceed in Australia.
Editas is developing a gene-editing therapy. The trial is in the Phase 1/2 stage.
Wells Fargo’s upgrade moves its rating on Editas from Equal Weight to Overweight. The rating change followed the Australian clearance.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.